IL153656A0 - Methods and compositions for treating pain of the mucous membrane - Google Patents

Methods and compositions for treating pain of the mucous membrane

Info

Publication number
IL153656A0
IL153656A0 IL15365601A IL15365601A IL153656A0 IL 153656 A0 IL153656 A0 IL 153656A0 IL 15365601 A IL15365601 A IL 15365601A IL 15365601 A IL15365601 A IL 15365601A IL 153656 A0 IL153656 A0 IL 153656A0
Authority
IL
Israel
Prior art keywords
compositions
mucous membrane
methods
treating pain
mucosal
Prior art date
Application number
IL15365601A
Other languages
English (en)
Original Assignee
Epicept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicept Inc filed Critical Epicept Inc
Publication of IL153656A0 publication Critical patent/IL153656A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)
IL15365601A 2000-06-26 2001-06-26 Methods and compositions for treating pain of the mucous membrane IL153656A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22216400P 2000-06-26 2000-06-26
PCT/US2001/020322 WO2002000195A2 (en) 2000-06-26 2001-06-26 Methods and compositions for treating pain of the mucous membrane

Publications (1)

Publication Number Publication Date
IL153656A0 true IL153656A0 (en) 2003-07-06

Family

ID=22831130

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15365601A IL153656A0 (en) 2000-06-26 2001-06-26 Methods and compositions for treating pain of the mucous membrane
IL153656A IL153656A (en) 2000-06-26 2002-12-25 Compositions for treating pain of the mucous membrane

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153656A IL153656A (en) 2000-06-26 2002-12-25 Compositions for treating pain of the mucous membrane

Country Status (11)

Country Link
US (3) US20020013331A1 (xx)
EP (1) EP1296650B1 (xx)
JP (2) JP2004501181A (xx)
AT (1) ATE289802T1 (xx)
AU (1) AU2001270177A1 (xx)
CA (1) CA2413545A1 (xx)
DE (1) DE60109164T2 (xx)
ES (1) ES2239144T3 (xx)
IL (2) IL153656A0 (xx)
PT (1) PT1296650E (xx)
WO (1) WO2002000195A2 (xx)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
ES2427976T5 (es) 2000-07-31 2022-04-13 Takeda Pharma As Composición de sal de fentanilo para administración nasal
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US6602490B1 (en) * 2002-03-04 2003-08-05 Richard A. Cloonan Dental cleaning formulation and manufacturing process
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
US20040019022A1 (en) * 2002-07-25 2004-01-29 Karen Stec Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
US20050266090A1 (en) * 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
BRPI0410505A (pt) * 2003-05-07 2006-06-20 Dmi Biosciences Inc métodos e produtos para cuidados orais
US7106483B2 (en) * 2003-06-12 2006-09-12 Ricoh Company, Limited Optical scanner and image forming apparatus
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050136116A1 (en) * 2003-12-18 2005-06-23 Keith Whitehead Stabilized prednisolone sodium phosphate solutions
GB0330049D0 (en) * 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
JP2007517806A (ja) * 2004-01-15 2007-07-05 オーラル バイオサイエンス ピーティーワイ． リミテッド 口腔用麻酔ゲル
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US20060115785A1 (en) 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US7947508B2 (en) * 2004-11-30 2011-05-24 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US7766658B2 (en) * 2004-11-30 2010-08-03 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
NZ555247A (en) * 2004-12-23 2010-06-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US20080248090A1 (en) * 2005-05-09 2008-10-09 Sunnen Gerard V Graduated concentration sodium chloride patches for the treatment of dental conditions
US20060252010A1 (en) * 2005-05-09 2006-11-09 Sunnen Gerard V Sodium chloride pad for treatment of dental conditions
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
EP1749528A1 (en) 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
US8263047B2 (en) * 2005-09-29 2012-09-11 Wickenhauser Alan J Topical anesthetic for dental procedures
US8623334B1 (en) 2005-09-29 2014-01-07 Alan J. Wickenhauser Topical anesthetic
JP5217136B2 (ja) * 2005-10-18 2013-06-19 大正製薬株式会社 直腸、尿道および膣適用用半固形状製剤。
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
US20070231396A1 (en) * 2006-03-29 2007-10-04 Ray Charles D Medication spray formulation
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
CN102218077A (zh) * 2006-08-01 2011-10-19 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008060764A2 (en) * 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
BRPI0807880A2 (pt) * 2007-03-02 2014-06-17 Combe Internat Ltd Composição anestésica em spray.
EP1964552B1 (en) * 2007-03-02 2009-08-26 Flamek Corp OÜ Analgesic composition of topically applied nonsteoridal antiinflammatory drugs and opioids
US20080305149A1 (en) * 2007-06-11 2008-12-11 Thomas Hirt Mucoadhesive vesicles for drug delivery
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US10512597B2 (en) * 2007-09-06 2019-12-24 Colgate-Palmolive Company Controlled surface gelling of mucoadhesive polymers on oral mucosa
WO2009046864A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of the human pancreatic polypeptide as a therapeutic agent
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2705681C (en) 2007-11-13 2013-06-18 Meritage Pharma, Inc. Corticosteroid compositions
EP2234625B8 (en) * 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
CN102014957B (zh) 2008-04-21 2014-12-10 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2306975A4 (en) 2008-07-21 2012-10-31 Otonomy Inc CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS
DE102008037682A1 (de) 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
CA2734763C (en) 2008-08-20 2016-06-28 Ranjan Dohil Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US20110117175A1 (en) * 2009-11-18 2011-05-19 Rosenbaum Richard J Sweet analgesic for use in medical procedures or treatments
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
WO2011066201A2 (en) * 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Methods and systems for treating and preventing cardiac injury in dystrophic subjects
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
HUE053776T2 (hu) * 2011-04-29 2021-07-28 Moberg Pharma Ab Gyógyszerészeti készítmény, amely helyi érzéstelenítõként bupivakaint tartalmaz szájban vagy torokban történõ helyi adagoláshoz
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
US9717667B2 (en) 2012-12-20 2017-08-01 Colgate-Palmolive Company Oral care composition containing ionic liquids
MX354123B (es) 2013-02-07 2018-02-14 Galvan Gonzalez Tomas Bernardo Composición antiséptica oral para tratamiento de mucositis oral.
US20140371305A1 (en) * 2013-06-14 2014-12-18 Professional Compounding Centers Of America Mupirocin Antibiotic Composition
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
WO2016070826A1 (zh) * 2014-11-05 2016-05-12 四川海思科制药有限公司 一种罗哌卡因缓释凝胶制剂及其制备与应用
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
US9943074B2 (en) * 2015-02-27 2018-04-17 Stanley James Balgaard Hinging and rotating coupler mechanism for avian spinning wing decoy
BR112018001900A2 (pt) 2015-07-28 2018-09-18 Otonomy, Inc. composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
EP3628314B1 (en) 2017-04-19 2023-07-26 Otsuka Pharmaceutical Factory, Inc. Olanexidine as anti-inflammatory agent
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051234A (en) 1975-06-06 1977-09-27 The Procter & Gamble Company Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US5225196A (en) 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
DE3522550A1 (de) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US4855142A (en) 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
US5906810A (en) 1987-03-17 1999-05-25 Turner; Robert E. Formulations and uses thereof in the prevention and treatment of oral lesions
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5219861A (en) 1988-12-21 1993-06-15 Chugai Seiyaku Kabushiki Kaisha 6 β-Thiomorphine derivatives
US5292362A (en) 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
US5662924A (en) 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5972906A (en) 1991-07-03 1999-10-26 Hyal Pharmaceutical Corporation Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof
US5589840A (en) 1991-11-05 1996-12-31 Seiko Epson Corporation Wrist-type wireless instrument and antenna apparatus
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4223004A1 (de) 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5496811A (en) 1992-08-28 1996-03-05 Pharmos Corp. Submicron emulsions as ocular drug delivery vehicles
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5817625A (en) 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
JPH08508472A (ja) 1993-03-26 1996-09-10 ダブリュー．エイチ．エム． マーカス フランシスカス ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5395318A (en) 1994-01-24 1995-03-07 Kaprelian; Edward K. Method and apparatus for wound treatment
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
IT1273742B (it) 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
US5958379A (en) 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
US5635540A (en) 1994-12-09 1997-06-03 The University Of Virginia Patent Foundation Stabilized topical pharmaceutical preparations
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5713852A (en) 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
JP2002516617A (ja) * 1995-06-16 2002-06-04 メドロジック グローバル コーポレイション 反応性ポリマー網状構造体及びその使用法
EP0832151A2 (en) * 1995-06-16 1998-04-01 Gel Sciences, Inc. Responsive polymer networks and methods of their use
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
FR2742989B1 (fr) 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5667773A (en) 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
US5972932A (en) * 1996-03-25 1999-10-26 Eli Lilly And Company Anesthetic method and composition
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP0829481A1 (en) 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
WO1998026770A2 (en) * 1996-12-16 1998-06-25 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
US5811078A (en) 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5798093A (en) 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5849762A (en) 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US5989535A (en) 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment
ES2252865T3 (es) * 1997-09-26 2006-05-16 Noven Pharmaceuticals, Inc. Composiciones bioadhesivas y metodos para la administracion topica de agentes activos.
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
ME00527B (me) * 1997-12-22 2011-10-10 Euro Celtique Sa Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US7700122B1 (en) 1998-07-16 2010-04-20 Memorial Sloan-Kettering Cancer Center Topical compositions comprising an opioid analgesic and an NMDA antagonist
FR2781156B1 (fr) * 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane

Also Published As

Publication number Publication date
US20020013331A1 (en) 2002-01-31
AU2001270177A1 (en) 2002-01-08
WO2002000195A3 (en) 2002-08-15
EP1296650B1 (en) 2005-03-02
JP2004501181A (ja) 2004-01-15
IL153656A (en) 2010-05-31
US20020192288A1 (en) 2002-12-19
PT1296650E (pt) 2005-06-30
US6509028B2 (en) 2003-01-21
JP2009001574A (ja) 2009-01-08
DE60109164D1 (de) 2005-04-07
ES2239144T3 (es) 2005-09-16
US20030124190A1 (en) 2003-07-03
CA2413545A1 (en) 2002-01-03
WO2002000195A2 (en) 2002-01-03
DE60109164T2 (de) 2005-12-29
EP1296650A2 (en) 2003-04-02
ATE289802T1 (de) 2005-03-15

Similar Documents

Publication Publication Date Title
IL153656A0 (en) Methods and compositions for treating pain of the mucous membrane
WO2004004650A3 (en) Antibacterial formulations
ATE525061T1 (de) Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
WO2002014311A3 (en) Urea compounds and methods of uses
AU1211302A (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
WO2002091999A3 (en) Treatment for wounds
WO2003018619A3 (en) Antimicrobial and anti-inflammatory peptides
AU1997795A (en) Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
ATE363271T1 (de) Verfahren zur verbesserung der grösse und des aussehens einer wunde
PL344111A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities
AU2764495A (en) Compositions and methods for treating mast-cell mediated conditions
WO2002007669A3 (en) Phospholipid derivatives of valproic acid and mixtures thereof
WO2003003997A3 (de) Verwendung von hopfen- bzw. hopfen-malz-extrakten in kosmetischen oder dermatologischen zubereitungen
AU2003270498A1 (en) Topical veterinary compositions and methods for the treatment and prevention of infection
HUP0301506A3 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
WO2000030660A3 (de) Hyperforin als zytostatikum sowie hyperforin-salbe oder -creme als applikationsform
ZA979647B (en) Heterocyclic compounds, compositions and uses.
MXPA03011622A (es) Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas.
CA2277207A1 (en) Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and a preparation containing dichlorobenzyl alcohol
CA2404210A1 (en) Pharmaceutical gel composition
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
WO2003032915A3 (en) Viral inhibition by n-docosanol
AU5630399A (en) Use of at least a10-hydroxy-2- decenoic acid derivative in composition for promoting skin scaling
HU9603309D0 (en) Acylated enol derivatives as prodrugs of elastase inhibitors
WO2003002084A3 (en) Fragrance and flavour compositions